Cargando…

Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis

BACKGROUND: Hyperuricemia is reported to be related to rapid progression of renal function in patients with chronic kidney disease (CKD). Allopurinol, a uric acid lowering agent, protects renal progression. However, it is not widely used in patients with CKD because of its serious adverse event. Feb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Sollip, Kim, Hyun-Jung, Ahn, Hyeong-Sik, Oh, Se Won, Han, Kum Hyun, Um, Tae-Hyun, Cho, Chong-Rae, Han, Sang Youb
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Nephrology 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592895/ https://www.ncbi.nlm.nih.gov/pubmed/28904879 http://dx.doi.org/10.23876/j.krcp.2017.36.3.274

Ejemplares similares

The potential renoprotection of xanthine oxidase inhibitors: Febuxostat versus allopurinol
por: Ryu, Dong-Ryeol
Publicado: (2017)

Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients
por: Li, Yanchun, et al.
Publicado: (2019)

Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease
por: Tsuruta, Yuki, et al.
Publicado: (2014)

Comparison of Febuxostat and Allopurinol in the Treatment of Patients with Chronic Kidney Disease Stage 3∼5 with Hyperuricemia
por: Liao, Zhimin, et al.
Publicado: (2022)

Comparative Renoprotective Effect of Febuxostat and Allopurinol in Predialysis Stage 5 Chronic Kidney Disease Patients: A Nationwide Database Analysis
por: Hsu, Yun‐Shiuan O., et al.
Publicado: (2019)

Comparison of efficacy and safety between febuxostat and allopurinol in early post‐renal transplant recipients with new onset of hyperuricemia
por: Shen, Xiaoju, et al.
Publicado: (2018)

Diabetes and gout: efficacy and safety of febuxostat and allopurinol
por: Becker, M A, et al.
Publicado: (2013)

Comparison of Commercial Genetic-Testing Services in Korea with 23andMe Service
por: Kim, Sollip, et al.
Publicado: (2014)

Four-Week Effects of Allopurinol and Febuxostat Treatments on Blood Pressure and Serum Creatinine Level in Gouty Men
por: Kim, Hyun Ah, et al.
Publicado: (2014)

Comparison between the Effects of Allopurinol and Febuxostat on the Survival of Patients on Maintenance Hemodialysis
por: Kang, Seok Hui, et al.
Publicado: (2023)

Management of hyperuricemia in gout: focus on febuxostat
por: Reinders, Mattheus K, et al.
Publicado: (2010)

False-Positive Elevation of Creatine Kinase MB Mass Concentrations Caused by Macromolecules in a Patient who Underwent Nephrectomy for Renal Cell Carcinoma
por: Kim, Sollip, et al.
Publicado: (2014)

Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014–2017
por: Weisshaar, Stefan, et al.
Publicado: (2022)

Comparison of the Renoprotective Effect of Febuxostat for the Treatment of Hyperuricemia between Patients with and without Type 2 Diabetes Mellitus: A Retrospective Observational Study
por: Ito, Hiroyuki, et al.
Publicado: (2016)

Switching from allopurinol to febuxostat: efficacy and tolerability in hemodialysis patients
por: Mitsuboshi, Satoru, et al.
Publicado: (2015)

Evaluation of effect of allopurinol and febuxostat in behavioral model of depression in mice
por: Karve, Ashwini V., et al.
Publicado: (2013)

Comparison of the Effects of Allopurinol and Febuxostat on the Values of Triglycerides in Hyperuricemic Patients
por: Ziga-Smajic, Nermina, et al.
Publicado: (2020)

Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression
por: Park, Seokwoo, et al.
Publicado: (2022)

Sex difference in heart failure risk associated with febuxostat and allopurinol in gout patients
por: Cheng, Ching-Lan, et al.
Publicado: (2022)

Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial
por: Suzuki, Satoshi, et al.
Publicado: (2021)

First Case of Intracranial Mycotic Aneurysm Caused by Prevotella intermedia Associated with Chronic Sinusitis in a Korean Adult
por: Park, Hea Ree, et al.
Publicado: (2020)

Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol
por: Pawar, Ajinkya, et al.
Publicado: (2021)

African American patients with gout: efficacy and safety of febuxostat vs allopurinol
por: Wells, Alvin F, et al.
Publicado: (2012)

Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
por: Guan, Xudong, et al.
Publicado: (2022)

Associations between Renal Hyperfiltration and Serum Alkaline Phosphatase
por: Oh, Se Won, et al.
Publicado: (2015)

Febuxostat in the management of hyperuricemia and chronic gout: a review
por: Hu, Miao, et al.
Publicado: (2008)

Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout
por: Gaffo, Angelo L, et al.
Publicado: (2010)

Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease
por: Akimoto, Tetsu, et al.
Publicado: (2014)

Febuxostat: A Novel Agent for Management of Hyperuricemia in Gout
por: Bisht, Manisha, et al.
Publicado: (2011)

Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia
por: MacDonald, Thomas M, et al.
Publicado: (2014)

Allopurinol for prevention of progression of kidney disease with hyperuricemia
por: Pai, B. H. Santhosh, et al.
Publicado: (2013)

Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study
por: Rey, Amayelle, et al.
Publicado: (2019)

Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia
por: Beara-Lasic, Lada, et al.
Publicado: (2010)

Real‐time display of laboratory testing status improves satisfaction levels in an emergency department: A pilot study
por: Chang, Jeonghyun, et al.
Publicado: (2020)

Clinical and Microbiological Characteristics of Chryseobacterium indologenes Bacteremia: A 20-Year Experience in a Single University Hospital
por: Chang, Jeonghyun, et al.
Publicado: (2023)

Cost-effectiveness of allopurinol versus febuxostat in the treatment of gout patients: A systematic review
por: Rezapour, Aziz, et al.
Publicado: (2020)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Gao, Linggen, et al.
Publicado: (2021)

Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients
por: Sofue, Tadashi, et al.
Publicado: (2014)

SAT-079 Renal Protective Effects Of Topiroxostat And Febuxostat In Hypertensives With Hyperuricemia.
por: Satoh, Fumitoshi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j3so73qdtqis6ochjbuerugcr0